Bio-Techne Corporation logo

Bio-Techne Corporation (TECH)

Market Closed
16 Jun, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
51. 63
+1.11
+2.2%
$
7.92B Market Cap
49.99 P/E Ratio
0.32% Div Yield
1,634,702 Volume
1.99 Eps
$ 50.52
Previous Close
Day Range
49.72 51.66
Year Range
46.01 83.62

Summary

TECH closed today higher at $51.63, an increase of 2.2% from yesterday's close, completing a monthly increase of 3.12% or $1.56. Over the past 12 months, TECH stock lost -29.03%.
TECH pays dividends to its shareholders, with the most recent payment made on May 30, 2025. The next estimated payment will be in In 2 months on Aug 30, 2025 for a total of $0.08.
The last earnings report, released on Apr 29, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.02%, based on the last three reports.
Bio-Techne Corporation has completed 1 stock splits, with the recent split occurring on Nov 30, 2022.
The company's stock is traded on 9 different exchanges and in various currencies, with the primary listing on NASDAQ (NGS) (USD).
Want to track TECH and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

TECH Chart

ScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics

ScaleReady Announces a G-Rex® Grant has been awarded to Immuneel Therapeutics

ST. PAUL, Minn. , June 10, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Immuneel Therapeutics has been awarded a $150,000 G-Rex® Grant to support process development aimed at enhancing the scalability and cost-effectiveness of CAR-T cell manufacturing in India.

Prnewswire | 6 days ago
Why Is Techne (TECH) Down 3% Since Last Earnings Report?

Why Is Techne (TECH) Down 3% Since Last Earnings Report?

Techne (TECH) reported earnings 30 days ago. What's next for the stock?

Zacks | 1 week ago
Is Bio-Techne Stock the Right Pick for Your Portfolio Now?

Is Bio-Techne Stock the Right Pick for Your Portfolio Now?

Bio-Techne's TECH GMP reagents, including GMP proteins and small molecules, remain a cornerstone of its cell therapy offering. Acquisitions have continued to play an important role in the company's efforts to expand its portfolio, as well as enter adjacent markets.

Zacks | 2 weeks ago

Bio-Techne Corporation (TECH) FAQ

What is the stock price today?

The current price is $51.63.

On which exchange is it traded?

Bio-Techne Corporation is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is TECH.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 7.92B.

Has Bio-Techne Corporation ever had a stock split?

Bio-Techne Corporation had 1 splits and the recent split was on Nov 30, 2022.

Bio-Techne Corporation Profile

Biotechnology Industry
Healthcare Sector
Mr. Kim Kelderman CEO
NASDAQ (NGS) Exchange
09073M104 Cusip
US Country
3,100 Employees
19 May 2025 Last Dividend
30 Nov 2022 Last Split
9 Feb 1989 IPO Date

Overview

Bio-Techne Corporation operates at the forefront of the life science sector, providing a comprehensive range of products and services crucial for research, clinical diagnostics, and therapeutic development. With a global footprint, the company serves a diverse clientele spread across the United States, the United Kingdom, rest of Europe, Middle East, Africa, Greater China, and the rest of the Asia-Pacific region. Bio-Techne is structured into two main operational segments: Protein Sciences, and Diagnostics and Genomics, each addressing different needs within the life sciences and diagnostics sectors. Originally established in 1976 under the name Techne Corporation, the organization underwent a rebranding to Bio-Techne Corporation in November 2014 and is based in Minneapolis, Minnesota. This strategic evolution reflects its broadened focus beyond its initial scope, signaling its expansion into a comprehensive suite of technologies and services catering to the dynamic requirements of biological research and clinical diagnostics.

Products and Services

Bio-Techne Corporation distinguishes itself through its broad portfolio of products and services across two main segments:

  • Protein Sciences: The cornerstone of Bio-Techne's offerings, this segment focuses on the development and manufacturing of biological reagents critical for life science research, diagnostics, and cell and gene therapy advancements. Products include:
    • Cytokines and growth factors: Essential for studying cell signaling and communication.
    • Antibodies: Integral for detecting and quantifying target proteins.
    • Small molecules: Used in various experimental applications to modulate biological processes.
    • Tissue culture sera: Provides a nutritious environment for cell culture growth.
    • Cell selection technologies: Enables the isolation of specific cell types for research or therapeutic use.
    • Proteomic analytical tools: Includes instruments and immunoassays for protein analysis in biological fluids, facilitating automated western blot and multiplexed ELISA workflows.
  • Diagnostics and Genomics: This segment is geared towards the development and manufacture of products for the regulated diagnostics market as well as for research and clinical applications involving genomics and oncology. Offerings include:
    • Diagnostic products: Comprising controls, calibrators, and assays for quality assurance in diagnostic testing.
    • Exosome-based molecular diagnostic assays: Innovative solutions for detecting disease markers at a molecular level.
    • Tissue-based in-situ hybridization assays: Advanced tools for spatial genomic analysis and biopsy examination.
    • Genetic and oncology kits: Facilitate research and clinical applications in genetics and cancer diagnostics.
    • Carrier screening and oncology diagnostics: Support genetic testing and cancer detection and monitoring.
    • Molecular controls: Provide benchmarks for ensuring accuracy in molecular diagnostic tests.
    • Process control products: Essential for maintaining quality in hematology, blood chemistry, and coagulation diagnostics.

Contact Information

Address: 614 McKinley Place N.E.
Phone: 612 379 8854